Resistance to antibiotics used to treat harmful stomach infection doubles in 20 years, new study finds
22 October 2019
The study, which analysed 1,232 patients from 18 countries* across Europe, investigated resistance to antibiotics regularly taken for Helicobacter pylori (H. pylori) infection, a harmful bacterium associated with gastric ulcer, lymphoma and gastric cancer. Resistance to clarithromycin, one of the most established antimicrobials used to eradicate H. pylori, had increased from 9.9% in 1998 to 21.6% last year, with increases in resistance also seen for levofloxacin and metronidazole.
Further reading: United European Gastroenterology
Author(s): UEG
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
